白蛋白结合型紫杉醇治疗紫杉类耐药的复发性卵巢癌的临床疗效  

Effect of albumin combined with paclitaxel on the treatment of taxane resistance recurrent ovarian cancer

作　　者：陈杰[1] 陈春婷[1] 关慧[1] 董立娜[1] 刘睿敏 

机构地区：[1]哈尔滨医科大学附属肿瘤医院妇科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2016年第19期3101-3104,共4页Journal of Modern Oncology

基　　金：黑龙江省教育厅科学技术研究项目(编号:12531386)

摘　　要：目的:观察白蛋白结合型紫杉醇在既往紫杉类(紫杉醇、多西紫杉醇)耐药的复发性卵巢癌治疗中的近期疗效和安全性。方法:选取32例既往使用紫杉类药物治疗失败的复发性卵巢癌患者予以白蛋白结合型紫杉醇方案治疗。白蛋白结合型紫杉醇每周期计量为260mg/m^2,静脉滴注30min(用药前不予抗过敏处理),合并抗肿瘤药按常规方法给药,21天为一周期,每2个周期评估疗效及毒副反应。结果:32例患者全部可评估疗效。完全缓解(CR)0例(0.0%),部分缓解(PR)10例(31.3%),疾病稳定(SD)15例(46.9%),疾病进展(PD)7例(21.9%),客观有效率(ORR)31.3%,临床获益率(CBR)78.1%,中位无疾病进展时间(PFS)为3.8个月。主要毒副反应为高血压、骨髓抑制、恶心、呕吐、脱发、四肢麻木、肌肉关节酸痛,无化疗相关死亡病例。结论:白蛋白结合型紫杉醇治疗既往紫杉类耐药的复发性卵巢癌有较好的近期疗效,毒副反应可耐受。Objective：To observe the curative effect and security of albumin combined with paclitaxel on the treat-ment of recurrent ovarian cancer in taxanes（paclitaxel and docetaxel）resistance.Methods：Selecting 32 cases of tax-ane treatment failure patients with recurrent ovarian cancer to perform albumin in combination with paclitaxel treat-ment.Albumin in combination with paclitaxel,every cycle measurement was 260mg/m^2 ,intravenous drip for 30min. Combined antitumor medicine was administrated as rountine.21 days was a cycle ,every two cycles had to evaluate curative effect and side effects.Results：All 32 cases could be evaluated in curative effect,complete remission （CR） in 0 case （0.0%）,partial response （PR）in 10 cases （31.3%）,stable disease （SD）in 15 cases （46.9%）,dis-ease progression （PD）in 7 cases （21.9%）.Objective response rate （ORR）was 31.3%,and clinical benefit rate （CBR）was 78.1%.The median progression-free survival time （PFS）was 3.8 months.Main adverse reactions were high blood pressure,bone marrow suppression,nausea,vomiting,alopecia,limb numbness,muscle and joints pain,no chemotherapy related deaths.Conclusion：Albumin in combination with paclitaxel on the treatment of taxane resistance recurrent ovarian cancer have better curative effect and adverse reactions can be tolerated.

关 键 词：复发性卵巢癌 白蛋白结合型紫杉醇 紫杉类耐药 毒副反应 近期疗效 安全性 

分 类 号：R737.31[医药卫生—肿瘤]